Aldehyde dehydrogenase (ALDH) is an enzyme that is expressed in the liver and is required for the conversion of retinol (vitamin A) to retinoic acids. ALDH is also highly enriched in hematopoietic stem cells (HSCs) and is considered a selectable marker of human HSCs, although its contribution to stem cell fate remains unknown. In this study, we demonstrate that ALDH is a key regulator of HSC differentiation. Inhibition of ALDH with diethylaminobenzaldehyde (DEAB) delayed the differentiation of human HSCs that otherwise occurred in response to cytokines. Moreover, short-term culture with DEAB caused a 3.4-fold expansion in the most primitive assayable human cells, the nonobese diabetic͞severe combined immunodeficiency mouse repopulating cells, compared with day 0 CD34 ؉ CD38 ؊ lin ؊ cells. The effects of DEAB on HSC differentiation could be reversed by the coadministration of the retinoic acid receptor agonist, all-trans-retinoic acid, suggesting that the ability of ALDH to generate retinoic acids is important in determining HSC fate. DEAB treatment also caused a decrease in retinoic acid receptor-mediated signaling within human HSCs, suggesting directly that inhibition of ALDH promotes HSC self-renewal via reduction of retinoic acid activity. Modulation of ALDH activity and retinoid signaling is a previously unrecognized and effective strategy to amplify human HSCs.
H ematopoietic stem cells (HSCs) possess the unique capacity to self-renew and give rise to all mature lymphohematopoietic progeny throughout the lifetime of an individual (1, 2) . Several molecular pathways that regulate HSC self-renewal have now been identified, including Notch (3), HOXB4 (4), Wnt (5) , and bone morphogenetic protein signaling pathways (6) . The osteoblastic niche for HSCs within the bone marrow (BM) has also been characterized (7, 8) . Despite these advances in understanding HSC biology, clinical methods to amplify human HSCs have yet to be realized, and characterization of the pathways that regulate HSC self-renewal continues to evolve.
Two decades ago, Colvin et al. (9, 10) demonstrated that the intracellular enzyme, aldehyde dehydrogenase (ALDH), protected BM progenitors from the cytotoxic effects of cyclophosphamide by deactivation of its metabolite, 4-hydroxycyclophosphamide (9, 10) . Several isoforms of ALDH have been identified, with ALDH1 being the primary isoform expressed within human hematopoietic progenitors (11, 12) . Recent studies have shown that human and murine hematopoietic progenitors can be isolated by using a fluorescently labeled dye specific for ALDH activity (13) (14) (15) (16) and cord blood (CB) ALDH br lin Ϫ cells are enriched for nonobese diabetic͞severe combined immunodeficiency (NOD͞SCID) mouse repopulating cells [SCID-repopulating cells (SRCs)] (15, 16) . Although these data demonstrate that ALDH is a selectable marker for human stem͞progenitor cells, the HSC-specific function of ALDH remains unknown. In the liver, ALDH1 contributes primarily to the metabolism of retinol (vitamin A) into retinoic acid (17) . Because ALDH1 is also highly concentrated in HSCs, it is plausible that the primary function of ALDH1 in HSCs relates to its production of retinoids.
The biological actions of retinoids are mediated by the retinoic acid receptor (RAR) and retinoid X receptor (RXR), liganddependent transcription factors that are expressed in the nuclei of target cells (18) (19) (20) . Through its actions on these receptors, alltrans-retinoic acid (ATRA) induces cellular differentiation, tissue patterning, and embryonic development in vertebrates (18) (19) (20) (21) (22) . ATRA is also used therapeutically to induce the differentiation of acute promyelocytic leukemia cells, in which the characteristic 15;17 translocation results in a fusion protein (PML-RAR␣) that harbors dominant negative activity against the RAR␣ receptor (23) . In light of these data, we postulated that HSC differentiation might depend on retinoid signaling and that inhibition of ALDH, which is required for production of retinoic acids, could interfere with HSC differentiation. In this study, we demonstrate that ALDH activity is necessary for normal HSC differentiation to occur in response to cytokines and that inhibition of ALDH, coupled with early acting cytokines, is sufficient to induce the quantitative expansion of human SRCs. Our findings indicate that inhibition of ALDH activity and retinoid signaling can impart a robust expansion of HSCs.
Results

Inhibition of ALDH Delays the Differentiation of HSCs in Culture.
We first determined whether inhibition of ALDH activity in primary BM and CB CD34 ϩ CD38 Ϫ lin Ϫ cells affected the differentiation of HSCs when cultured for 7 days in the presence of thrombopoietin (20 ng͞ml), stem cell factor (SCF; 100 ng͞ml), and flt-3 ligand (50 ng͞ml), a cytokine combination which we have found optimizes the proliferation of human HSCs in culture (24) . FACS-sorted human CD34 ϩ CD38 Ϫ lin Ϫ cells were used because this population has been shown to be the most highly enriched population for human HSCs (25) . Treatment with 100 M diethylaminobenzaldehyde (DEAB) ϩ TSF significantly reduced ALDH activity in CD34 ϩ CD38 Ϫ cells compared with day 0 or after treatment with TSF alone, and Ͼ90% of day 0 CB CD34 ϩ CD38 Ϫ lin Ϫ cells demonstrated ALDH activity (Fig. 1a , P Ͻ 0.001 and P Ͻ 0.001). The progeny of CB and BM CD34 ϩ CD38 Ϫ lin Ϫ cells after 7 days of culture with DEAB ϩ TSF contained significantly higher percentages of primitive CD34 ϩ CD38 Ϫ cells compared with the day 7 progeny of TSF alone ( Fig. 1b and Fig. 5a , which is published as supporting information on the PNAS web site; P ϭ 0.02 and P ϭ 0.01, respectively). DEAB ϩ TSF cultures supported a mean 4-fold total cell expansion and a maintenance of absolute numbers of BM CD34 ϩ CD38 Ϫ cells compared with day 0. Conversely, TSF culture supported a mean 15-fold increase in total cells, but this increase was associated with a 5-fold decrease in BM CD34 ϩ CD38 Ϫ cell numbers compared with input (P ϭ 0.01). Table 1 (Fig. 2a) . At a dose of 0.5 ϫ 10 3 , no mice transplanted with day 0 CB CD34 ϩ CD38 Ϫ lin Ϫ cells or their progeny after culture with TSF alone or TSF ϩ DEAB demonstrated human hematopoietic cell engraftment. At doses of 1-2.5 ϫ 10 3 cells, only 3 of 15 mice (20%) transplanted with day 0 CD34 ϩ CD38 Ϫ lin Ϫ cells showed huCD45 ϩ cell engraftment (Fig. 2b) . Similarly, only 1 of 9 mice transplanted with the progeny of this dose after culture with TSF alone demonstrated human engraftment. In contrast, 8 of 16 mice Ϫ cells (mean 0.9%, range 0.02-3.5%, P ϭ 0.048) or their progeny after culture with TSF (0.7%, range 0.4-1.3%), indicating that DEAB-cultured progeny also had a higher in vivo proliferative potential than the day 0 HSCs or TSF-cultured cells. Poisson statistical analysis (24) (25) (26) (27) (28) indicated that the SRC frequency within day 0 CB CD34 ϩ CD38 Ϫ lin Ϫ cells was 1 in 7,500 cells (95% confidence interval of 1͞2,900 to 1͞30,000). The SRC frequency within the progeny of TSF-cultured CB CD34
ϩ CD38 Ϫ lin Ϫ cells was more than 2-fold reduced at 1 in 17,000 cells (confidence interval of 1͞3,800 to 1͞290,000). In contrast, the SRC frequency within the progeny of DEAB ϩ TSF-cultured CB CD34 ϩ CD38 Ϫ lin Ϫ cells was 1 in 2,200 cells (confidence interval of 1͞1,100 to 1͞4,900), which was 3.4-fold higher than day 0 CB CD34 ϩ CD38 Ϫ lin Ϫ cells and 7.7-fold higher than TSF-cultured progeny (P ϭ 0.056 and P ϭ 0.011, respectively). The human cell engraftment observed in all primary transplanted NOD͞SCID mice is summarized in Table 2 , which is published as supporting information on the PNAS web site. These data demonstrate that inhibition of ALDH not only inhibited the differen- tiation of HSCs but also promoted the amplification of HSCs in culture. Detailed flow cytometric analysis revealed extensive CD34 ϩ progenitor cell, CD19 ϩ B lymphoid, and CD33͞13 ϩ myeloid differentiation in mice transplanted with DEAB ϩ TSFcultured cells, demonstrating that a pluripotent repopulating cell was sustained during culture with DEAB (Fig. 2c) . Of note, the ratio of human CD19 ϩ B lymphoid cells to CD33͞CD13 ϩ myeloid cells detectable at 8 weeks in mice transplanted with day 0 CD34 ϩ CD38 Ϫ lin Ϫ cells was Ϸ2:1 (mean 3.2% CD19 ϩ cells to mean 1.7% CD13͞33 ϩ cells), whereas this ratio was 2.7:1 in mice transplanted with the progeny of CD34 ϩ CD38
Ϫ lin Ϫ cells after culture with DEAB ϩ TSF. These data suggest that inhibition of ALDH may have modestly inhibited the myeloid differentiation capacity of HSCs expanded under this condition.
Although our primary limiting dilution NOD͞SCID transplantation studies were not designed to achieve the necessary high levels (20-50%) of human CD45 ϩ cell chimerism to allow for secondary transplantation studies, we did perform a limited number of secondary transplants to assess for the presence of long-term repopulating stem cells within the DEAB-cultured populations. At 12 weeks after tail-vein transplantation of 75% of the total BM cells from primary recipients of DEAB ϩ TSF-cultured cells (2.5 ϫ 10 3 dose), 3 of the 5 mice analyzed demonstrated human hematopoietic cell engraftment via PCR analysis for a 1,171-bp fragment of human chromosome 17-specific ␣-satellite region (Fig. 2d) (29) . These results confirmed that inhibition of ALDH activity promoted the differential maintenance of long-term repopulating stem cells in culture.
DEAB Specifically Inhibits ALDH1 and Decreases Retinoic Acid Activity in HSCs.
To further test our hypothesis that ALDH contributes to HSC differentiation through the production of retinoic acids, we first evaluated the effects of ATRA on primary CB CD34 ϩ CD38
Ϫ lin Ϫ cells in culture. In contrast to DEAB treatment, which maintained a population of CD34 ϩ CD38 Ϫ cells in culture at day 7 (Fig. 3a-c) , treatment of CB CD34 ϩ CD38
Ϫ lin Ϫ cells with TSF ϩ 1 M ATRA resulted in a marked decline in CD34 ϩ cells in culture compared with TSF alone, and no CD34 ϩ CD38 Ϫ cells were detectable at day 7 (Fig. 3d) . Moreover, when we cultured CB CD34 ϩ CD38
Ϫ lin Ϫ cells with 1 M ATRA ϩ 100 M DEAB ϩ TSF, phenotypic differentiation of CD34 ϩ CD38
Ϫ cells again occurred, indicating that provision of extracellular retinoids overcame the effects of DEAB-induced inhibition of ALDH (Fig. 3e) . Taken together, these results suggested that ALDH might contribute to HSC differentiation through its production of intracellular retinoids. Analysis of CFC content within cultures treated with ATRA ϩ TSF demonstrated a Ͼ10-fold reduction in CFCs within ATRAtreated cultures compared with the progeny of TSF alone, indicating that ATRA either inhibited CFC formation or promoted terminal progenitor cell differentiation, thereby reducing CFC numbers (data not shown). As further support of the relationship between ALDH activity and retinoid production in HSCs, we also cultured human CB CD34 ϩ CD38 Ϫ lin Ϫ cells with 100 nM of 4-(E-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl) benzoic acid (TTNPB), an RAR-specific agonist, with TSF and observed a marked differentiation of cells by day 7 of culture. The effect of TTNPB also overcame the effect of DEAB toward inhibiting HSC differentiation (Fig. 6 a and b , which is published as supporting information on the PNAS web site). The addition of 100 M of LGD101268, a synthetic agonist of the RXR (courtesy of Ligand Pharmaceuticals, San Diego, CA), also completely overcame the inhibitory effect of DEAB on HSC differentiation during culture (Fig. 6 c and d) . Lastly, the addition of 100 nM of 1,25-dihydroxyvitamin D 3 (vitamin D), which has been shown to induce the differentiation of human hematopoietic progenitor cells (30) , also overcame the effects of DEAB on HSCs in culture ( Fig.  6 e and f ) . Interestingly, the addition of DEAB did appear to increase the maintenance of CD34ϩ progenitor cells in culture when combined with either the RAR agonist, the RXR agonist, or vitamin D, suggesting that inhibition of ALDH activity moderately slowed the differentiation of HSCs that occurred in response to these three ligands (Fig. 6 a-f ) . Nonetheless, these data demonstrated that the addition of exogenous retinoids, rexinoids, or vitamin D generally overcame the effect of DEAB toward inhibiting HSC differentiation, further supporting our hypothesis that ALDH mediates its effects on HSC fate via its contribution to retinoid production. Because several isoforms of ALDH exist (31), we sought to determine whether DEAB was specifically inhibiting ALDH1, which is known to be highly expressed in HSCs (11, 14, 32) and is the predominant regulator of retinoic acid synthesis in mammals (31) , versus other isoforms. First, we observed that treatment of HSCs with DEAB for 7 days caused a 2-fold decrease in the expression of cEBP (Fig. 3f ) , which is under the control of RAR signaling (33) , confirming that inhibition of ALDH activity with DEAB caused a decrease in retinoid activity in human HSCs. Secondly, the addition of 1 M retinaldehyde, which is a specific substrate for ALDH1, to HSC cultures caused an 8.4-fold increase in cEBP expression in HSCs, confirming the contribution of ALDH1 to retinoic acid activity in these cells. However, when DEAB was added to HSC cultures supplemented with retinaldehyde, the effect of retinaldehyde on cEBP expression was significantly reduced, demonstrating that DEAB significantly inhibited the activity of ALDH1 in HSCs, which consequently caused a marked decrease in retinoid signaling in these primitive cells (Fig. 3f ) .
Inhibition of ALDH Activity Up-Regulates HOXB4 Expression in Human
HSCs. Because HOXB4 and Notch have established roles in HSC self-renewal (3, 4), we sought to determine whether ALDH inhibition might regulate HSC self-renewal by altering the transcription of either of these target genes. Interestingly, culture of primary CB CD34 ϩ CD38
Ϫ lin Ϫ cells with TSF alone caused a 5-fold decrease in HOXB4 transcription compared with day 0 CB CD34 ϩ CD38 Ϫ lin Ϫ cells, whereas the addition of DEAB to TSF maintained HOXB4 expression at 70% of input levels (Fig. 4) . Conversely, treatment with DEAB did not alter Notch transcription compared with TSF alone. Taken together, these data indicate that inhibition of ALDH may also promote HSC self-renewal via discrete interactions with other established pathways, such as HOXB4, although the organization of these signals is yet to be elucidated.
Discussion
Improved characterization of the pathways that regulate HSC self-renewal will facilitate the development of therapies to amplify HSCs in vitro or in vivo for clinical purposes. In this study, we have characterized the novel contributions of the enzyme ALDH and retinoid signaling to human HSC differentiation and self-renewal. ALDHs are NAD(P) ϩ -dependent enzymes that oxidize a large number of aldehydes to their corresponding carboxylic acids (17, 31) . Several different ALDH isoforms (30) have been identified that are responsible for the metabolism of ethanol (34) , catecholamines, (14) and the conversion of vitamin A to its active metabolite, retinoic acid (17) . ALDH is also a selectable marker of human stem͞progenitor cells (13, 15, 16) . However, the contribution of ALDH activity to HSC function has remained unknown. In this study, we show that inhibition of ALDH activity with DEAB delayed the phenotypic and functional maturation of HSCs in response to thrombopoietin, SCF, and flt-3 ligand. ALDH inhibition, coupled with TSF, also gave rise to a 3.4-fold increase in SRCs in short-term culture, whereas treatment with TSF alone was associated with a 2-fold reduction in SRC content compared with input. Importantly, secondary transplant studies confirmed that long-term repopulating stem cells were maintained in cultures treated with DEAB. These studies indicate that ALDH plays a critical role in human HSC differentiation. Moreover, inhibition of ALDH, when combined with early acting cytokines, is sufficient to induce the amplification of human HSCs.
In light of the observed effects of ALDH inhibition on the amplification of human HSCs in culture, we also sought to determine the mechanism through which this effect occurred. Because ALDH1 is the predominant isoform within HSCs (11, 14, 32) and is the dominant isoform in mammals that regulates the conversion of retinaldehydes to retinoic acids (31), we tested whether DEAB specifically inhibited ALDH1 activity in HSCs and the effect this had on RAR-response genes. Our studies confirmed that DEAB treatment blocked the capacity for HSCs to convert retinaldehyde into retinoic acids by virtue of a marked decrease in expression of cEBP, which is an RAR-specific response gene. Because ALDH1 is the dominant isoform required for the conversion of retinaldehyde to retinoic acids, these results also confirmed that the effect of DEAB on HSC differentiation was predominantly mediated through inhibition of ALDH1. Taken together, these data provide strong evidence that ALDH1 mediates the differentiation of HSCs via production of intracellular retinoic acids and that targeted inhibition of this enzyme promotes HSC self-renewal via inhibition of retinoic acid signaling.
The data presented here demonstrate that modulation of retinoid signaling can induce the expansion of human HSCs. There are several implications of these observations. First, the functional role of ALDH1 in HSC fate and the link between ALDH1 activity, retinoid signaling, and HSC self-renewal has not been previously described. Interestingly, Purton et al. (35, 36) reported that culture of murine c-kit ϩ sca-1 ϩ lin Ϫ cells with ATRA for 14 days enhanced the maintenance of cells with in vivo repopulating capacity as compared with culture with cytokines alone. These results appear to contrast with our observations that inhibition of ALDH1 and retinoid signaling induces the expansion of human HSCs. These differences may be explained by differences in the contribution of ALDH1 activity to HSC fate between mice and humans or differences in the repopulating assays being performed. We have initiated additional studies to determine whether the function of ALDH1 in hematopoiesis is conserved in both humans and mice. Our data also suggest that cytokines, such as thrombopoietin, SCF, and flt-3 ligand, induce HSC differentiation via induction of retinoid signaling, perhaps mediated through increased ALDH1 activity. This hypothesis is supported by the recent observation that another cytokine, IL-3, induces hematopoietic progenitor cell differentiation via activation of Stat5 which, in turn, activates retinoid signaling (37) . Our results also have implications for the development of strategies to amplify human HSCs for clinical purposes. We performed these studies on primary human HSCs, and our observations are therefore directly translatable to clinical protocols to expand human HSCs. Moreover, in contrast to other reported strategies to expand HSCs in vitro (5, 38) , the approach we have described does not depend on the genetic modification of HSCs or coculture with surrogate stromal cell niches to achieve potency (39, 40) . Finally, the observed in vivo multilineage differentiation of DEAB-treated HSCs transplanted in NOD͞SCID mice demonstrates that ALDH inhibition does not significantly alter the normal differentiation program of human HSCs. It will be important to further augment the expansion of HSCs described here via the combination of ALDH inhibitors with other ligands capable of inhibiting HSC differentiation programs. In addition, it will also be important to directly modulate RAR and RXR signaling in primary HSCs. We have observed that a selective RXR modulator causes the enhancement of SRC content in short-term culture in a manner highly comparable to ALDH inhibition (J.P.C., D.P.M., G.G.M., and R.S., unpublished data). In summary, our data suggest that ALDH1 functions fundamentally in HSCs to promote differentiation via the production of retinoic acids. The notion that ALDH1 is both a selectable marker of stem and progenitor cells (13, 14) and a critical regulator of stem cell differentiation appears counterintuitive. However, because a fundamental property of HSCs is the ongoing production of all mature hematopoietic cells, it is not surprising that HSCs would possess a differentiation program (e.g., ALDH1 activity, production of retinoic acids) that can be activated early in their lifespan, particularly in response to external stimuli (e.g., cytokines). Production of large numbers of HSCs lacking such an early differentiation capacity would also be potentially pathologic. Therefore, we believe it is consistent with normal hematopoiesis that HSCs might possess in vivo repopulating capacity while also carrying the critical capacity for fairly rapid differentiation in response to external signals. The results presented here demonstrate that inhibition of ALDH and retinoid activity is sufficient to induce the expansion of human HSCs. Analysis of in Vitro Hematopoietic Activity of Human CD34 ؉ CD38 ؊ lin ؊ Cells After Culture with DEAB. Primary human BM and CB CD34 ϩ CD38 Ϫ lin Ϫ cells were placed in culture with 20 ng͞ml thrombopoietin, 100 ng͞ml stem cell factor, and 50 ng͞ml flt-3 ligand (TSF, R & D Systems), a cytokine combination which we have previously found to induce human stem and progenitor cell proliferation and differentiation in vitro (24) . BM or CB CD34 ϩ CD38 Ϫ lin Ϫ cells at a dose of 0.5-1 ϫ 10 4 were cultured for 7 days with and without 100 M DEAB (courtesy of M. Colvin, Duke University). At day 7, cell counts and immunophenotypic analysis was performed on progeny cells by using anti-human CD34 and CD38 mAbs (Becton Dickinson) and isotype control IgG mAbs and compared with day 0 (input) staining. Fourteen-day methylcellulose CFC assays were performed in triplicate as we have previously described (24, 26) (for details, see Supporting Methods).
Methods
BM and CB CD34 ϩ CD38 Ϫ lin Ϫ cells were also placed in culture with TSF with and without ATRA (Sigma-Aldrich), TTNPB (Sigma-Aldrich), LGD101268, or 1-␣,25-dihydroxyvitamin D 3 (Sigma-Aldrich) with or without DEAB to determine the relationship between ALDH inhibition and retinoic acid signaling in human HSCs (see Supporting Methods for details).
In Vivo Long-Term Repopulating Assays in NOD͞SCID Mice. NOD͞ SCID mice (41) 
